Boehringer Ingelheim Corporation's Afatinib Receives Positive CHMP Opinion for Patients With EGFR Mutation Positive Lung Cancer in European Union

Published: Jul 26, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for afatinib – which has been submitted under the European Union brand name GIOTRIF®*. Afatinib is the first irreversible ErbB Family Blocker for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).

Help employers find you! Check out all the jobs and post your resume.

Back to news